Oralair (Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate)

Oralair is an allergen immunotherapy tablet that targets grass‑pollen‑driven allergic disease.

• Seasonal allergic rhinitis: reduces nasal congestion, sneezing and itching during grass pollen season.
• Allergic rhinoconjunctivitis: alleviates eye irritation and nasal symptoms linked to grass pollen exposure.
• Long‑term disease modification: may decrease the need for symptomatic allergy medications over multiple pollen seasons.

• Oralair delivers standardized grass‑pollen allergen extracts to the sublingual mucosa, where repeated exposure induces immune tolerance. The process shifts the immune response from an IgE‑dominant pathway toward increased IgG4 production and regulatory T‑cell activity, reducing hypersensitivity to the specific grass pollen allergens.

Oralair may cause local and systemic reactions following sublingual administration.

Common Side Effects

• Oral itching or mild irritation at the site of tablet placement.
• Throat discomfort or mild soreness.
• Transient mouth swelling.
• Mild gastrointestinal upset such as nausea.
• Headache.
• Mild fatigue.

Serious or Rare Side Effects

• Anaphylaxis or severe systemic allergic reaction.
• Severe throat swelling that interferes with breathing.
• Persistent wheezing or bronchospasm.
• Angio‑edema of the lips or face.
• Cardiovascular symptoms such as hypotension.
• Severe urticaria or widespread rash.

Before starting Oralair, patients should be evaluated for suitability and instructed on proper use.

• Contraindication: Known severe allergy to any component of the tablet.
• Medical review: Assess for uncontrolled asthma or recent severe allergic reactions.
• Monitoring: Observe for at least 30 minutes after the first dose for any systemic reaction.
• Pregnancy: Use only if the potential benefit outweighs risk; data are limited.
• Breastfeeding: Caution advised; discuss with a healthcare professional.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Oralair has a low potential for drug‑drug interactions, but certain co‑medications may modify its safety profile.

Major Interactions (Avoid)

• Beta‑beta‑lactam antibiotics: may increase risk of systemic allergic reactions.
• ACE inhibitors: can exacerbate angio‑edema risk when combined with allergen exposure.
• NSAIDs: may heighten the chance of severe oral itching and swelling.

Moderate Interactions (Monitor Closely)

• Antihistamines: may mask early signs of an allergic reaction, delaying detection.
• Corticosteroids: concurrent use may alter immune response to the tablet.
• Leukotriene receptor antagonists: monitor for additive respiratory symptoms.